TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06934538: First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

Sponsor: Brenus Pharma · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT06934538 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06934538 Rescue Dossier →